ng-nitroarginine methyl ester has been researched along with Cancer of Prostate in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bellone, M; Capuano, G; Freschi, M; Generoso, L; Grioni, M; Jachetti, E; Ricupito, A; Rigamonti, N | 1 |
Abraham, NG; Acquaviva, R; Barbagallo, I; Cardile, V; Di Giacomo, C; Santangelo, R; Sorrenti, V; Vanella, L | 1 |
2 other study(ies) available for ng-nitroarginine methyl ester and Cancer of Prostate
Article | Year |
---|---|
Modulators of arginine metabolism do not impact on peripheral T-cell tolerance and disease progression in a model of spontaneous prostate cancer.
Topics: Adenocarcinoma; Animals; Arginine; CD11b Antigen; Cell Proliferation; Disease Progression; Immune Tolerance; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Myelopoiesis; NG-Nitroarginine Methyl Ester; Piperazines; Prostatic Neoplasms; Purines; Sildenafil Citrate; Sulfones; T-Lymphocytes; Tumor Cells, Cultured | 2011 |
The DDAH/NOS pathway in human prostatic cancer cell lines: antiangiogenic effect of L-NAME.
Topics: Amidohydrolases; Angiogenesis Inhibitors; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Enzyme Inhibitors; Humans; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Prostatic Neoplasms; Vascular Endothelial Growth Factor A | 2011 |